Tyra Biosciences to Present at UBS Biotech Management Live Call Series on Achondroplasia and Growth Disorders.
ByAinvest
Monday, Jul 21, 2025 4:07 pm ET1min read
SNAP--
TYRA--
UBS--
Tyra Biosciences announced its participation in the UBS Biotech Management Live Call Series, where management will discuss achondroplasia and growth disorders in a virtual fireside chat. The event will take place on July 25, 2025, and will feature Todd Harris, CEO, Doug Warner, MD, CMO, and Alan Fuhrman, CFO, among others. The company's precision medicine platform, SNÅP, enables rapid drug design through molecular SNÅPshots that predict genetic alterations causing acquired resistance to existing therapies. Tyra Biosciences is focused on developing next-generation precision medicines targeting FGFR biology.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet